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Objectives. Our aim was to present the immediate and inter-
mediate long-term results of the application of retrograde non-
transseptal balloon mitral valvuloplasty (RNBMV) in four coop-
erating centers from Greece and India.
Background. RNBMV is a purely transarterial method of
balloon valvuloplasty, developed with the aim to avoid complica-
tions associated with transseptal catheterization. Only single-
center experience with RNBMV has been previously reported.
Methods. The procedure was attempted in 441 patients with
symptomatic mitral stenosis (320 women, 121 men, mean age [6
SD] 44 6 11 years, mean echocardiographic score [6 SD] 7.7 6
2.0) from 1988 to 1996. Three hundred eighty-five patients with
successful immediate outcome were followed clinically for a mean
[6 SD] of 3.5 6 1.9 (range, 0.5–9.1) years.
Results. A technically successful procedure was achieved in 388
(88%) cases. The echocardiographic score (p < 0.001), male
gender (p 5 0.005), preprocedural mitral regurgitation (p 5
0.007) and previous surgical commissurotomy (p 5 0.029) were
unfavorable predictors of immediate outcome. Complications
included death (0.2%), severe mitral regurgitation (3.4%) and
injury of the femoral artery (1.1%). Event-free (freedom from
cardiac death, mitral valve surgery, repeat valvuloplasty and
NYHA class > II symptoms) survival rates (6 SEM) were 100%,
96.9 6 0.9%, 89.8 6 1.9% and 75.5 6 5.5% at 1, 2, 4 and 9 years,
respectively. The echocardiographic score (p < 0.001), NYHA
class (p 5 0.008) and postprocedural mitral valve area (p 5
0.009) were significant independent predictors of intermediate
long-term outcome.
Conclusions. Multicenter experience indicates that RNBMV is
a safe and effective technique for the treatment of symptomatic
mitral stenosis. As with the transseptal approach, patients with
favorable mitral valve anatomy derive the greatest immediate and
intermediate long-term benefit from this procedure.
(J Am Coll Cardiol 1998;32:1009–16)
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More than a decade after its introduction by Inoue et al. (1),
percutaneous balloon mitral valvuloplasty has been established
as an effective alternative to surgery for the treatment of mitral
stenosis. In its most widely employed variations, the technique
of valvuloplasty involves puncture of the interatrial septum
(1–5) and is associated with a small risk of serious complica-
tions including cardiac perforation, cardiac tamponade or the
creation of a significant left-to-right interatrial shunt (6,7). In
an effort to obviate the need for transseptal catheterization, an
alternative purely transarterial technique [retrograde non-
transseptal balloon mitral valvuloplasty (RNBMV)] was devel-
oped at the University of Athens, Athens, Greece. This
approach is based on the use of a specially designed, externally
steerable left atrial (LA) guiding catheter (Cordis, Europa
N.V.-Cat # 5RE-692) by means of which entry into the LA is
achieved retrogradely via the left ventricle (LV) (8,9).
Published data have so far reported only single-center
experience with RNBMV (10–13). In the present study, the
results of its application in four cooperating centers from two
countries are presented for the first time with emphasis placed
on the assessment of immediate results, development of com-
plications and intermediate long-term outcome of this tech-
nique.
Methods
Study population. From April 1988 until September 1996,
RNBMV was attempted by independent operators in 441
consecutive cases at the Athens University (n 5 293), Onassis
Cardiac Surgery Center (n 5 31) and Tzannio Hospital (n 5
16) in Greece and at the All India Institute of Medical Sciences
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(n 5 101) in New Delhi, India. Baseline characteristics of the
total patient population, as well as of the subgroups of Greek
and Indian patients, are summarized in Table 1. All patients
were symptomatic. Patients in atrial fibrillation were anticoag-
ulated for at least 2 months prior to valvuloplasty. Patients with
more than moderate mitral regurgitation (MR) or echocardio-
graphic evidence of LA thrombus were not considered eligible
for RNBMV. Echocardiographic score . 8 (14) was present in
131 patients (29.7%); subvalvular thickening grade $ 3 was
present in 83 (18.8%) patients. Fluoroscopic valve calcification
was present in 114 patients (25.9%).
Preprocedural evaluation. Within 48 h prior to valvulo-
plasty, all patients underwent a diagnostic workup including
evaluation of clinical status and echocardiographic examina-
tion.
Assessment of functional capacity was based on the criteria
of the New York Heart Association (NYHA). Echocardio-
graphic examination included M-mode, two-dimensional and
Doppler echocardiography. Transesophageal echocardiograms
were also performed in all but the first 41 treated patients. In
addition to the assessment of mitral anatomy, echocardiogra-
phy focused on the detection of LA thrombi and on the
quantification of concomitant MR and aortic or tricuspid valve
disease.
Cardiac catheterization and valvuloplasty. The study pro-
tocol was approved by the committees on human research of
the participating institutions. Written informed consent was
obtained by all patients after detailed description of the
procedure.
Diagnostic cardiac catheterization and RNBMV were per-
formed as previously described (9–13) (Fig. 1). In India, a
sheathless technique was employed in the majority of cases; for
the insertion of the balloon catheter in these procedures, the
groin incision was dilated with a 10 F dilator. At the Greek
centers, insertion of the balloon catheter was performed
through either an adjustable introducer (Medina-Schneider,
Europe, used during our early experience) or a 12 F sheath
(William Cook Europe, Bjaeverskov, Denmark, employed in
the last 250 Greek patients in this series).
In a total of 438 completed procedures, the single-balloon
technique was used in 240 cases [conventional single balloon in
220; Inoue balloon catheter modified by elongation of the
catheter shaft in 20 cases (12)], the twin-balloon (bifoil)
technique in 194 cases and the double-balloon bifemoral
Abbreviations and Acronyms
FA 5 femoral artery
FU 5 follow-up
LA 5 left atrial, left atrium
LV 5 left ventricle, left ventricular
MR 5 mitral regurgitation
MVA 5 mitral valve area
MVR 5 mitral valve replacement
NYHA 5 New York Heart Association
RNBMV 5 retrograde nontransseptal balloon mitral valvuloplasty







(n 5 101) p Value
Age, years 44 6 11 49 6 11 28 6 8 , 0.001
Males/females 121/320 63/277 58/43 , 0.001
Body surface area, m2 1.62 6 0.18 1.68 6 0.16 1.48 6 0.7 , 0.001
NYHA class 0.014
II 72 (16.3%) 65 (19.1%) 7 (6.9%) 0.004
III 324 (73.5%) 241 (70.9%) 83 (82.2%) 0.024
IV 45 (10.2%) 34 (10%) 11 (10.9%) NS
Atrial fibrillation 202 (45.8%) 186 (54.7%) 16 (15.8%) , 0.001
Previous commissurotomy 20 (4.5%) 18 (5.3%) 2 (1.9%) NS
Associated cardiac disease 0.020
Mild or moderate aortic valve disease 98 (22.2%) 86 (25.3%) 12 (11.9%) 0.004
Substantial aortic stenosis 1 (0.2%) — 1 (1%) NS
Conduction defect 4 (0.9%) 4 (1.2%) — NS
Substantial CAD 3 (0.7%) 3 (0.9%) — NS
LV ejection fraction (%) 61 6 13 60 6 13 64 6 10 0.006
Echocardiographic score
Leaflet mobility 2.1 6 0.6 2.2 6 0.6 1.9 6 0.5 , 0.001
Leaflet thickening 2.3 6 0.6 2.3 6 0.6 2.3 6 0.5 NS
Leaflet calcification 1.3 6 0.9 1.4 6 0.9 1.0 6 0.2 , 0.001
Subvalvular thickening 2.0 6 0.8 2.0 6 0.7 2.1 6 0.6 NS
Total score 7.7 6 2.0 7.8 6 2.0 7.4 6 1.6 NS
Mitral regurgitation 0.001
Mild 74 (16.8%) 69 (20.3%) 5 (4.9%) 0.001
Moderate 2 (0.5%) 2 (0.6%) — NS
Plus-minus values are mean 6 SD. CAD 5 coronary artery disease. Pts, patients.
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technique in four cases. The right brachial artery approach was
employed once.
During all procedures, preventive measures taken against
subvalvular damage included the following 1) Curving of the
LA catheter’s distal tip was always performed in the apical
region of the LV, and only then was the catheter rotated
counterclockwise and retracted to reach a point immediately
below the mitral valve. 2) Correct positioning of the catheter
was subsequently confirmed either by the recording of LA
pressures through the catheter or by the unobstructed forward
advancement of a J wire through its lumen into the LA cavity.
3) An additional safety check was performed after the intro-
duction of the stiff guidewire into the LA, by the insertion of a
flow-directed catheter into the LV over it. The balloon was
inflated in the LV outflow tract with a dilute dye solution or
carbon dioxide and was advanced toward the mitral valve; its
unobstructed movement was considered as proof of the fact
that the guidewire had passed correctly through the LV inflow
tract and had not become involved with the chordae tendineae
(10–12).
When involvement of the LA catheter with the subvalvular
apparatus was suspected, the catheter was either advanced
toward the LV apex and positioning manipulations were
repeated, or it was retracted into the ascending aorta after
complete release of its curved tip and was reintroduced into
the LV with the help of a guidewire (10–12). Performance of
these actions was necessitated very rarely and was successful at
all times.
Clinical follow-up. Clinical follow-up (FU) data were ob-
tained at 3, 6, and 12 months after RNBMV and at 1-year
intervals thereafter by direct interview with the patients.
Endpoints of FU were cardiac death, mitral valve replacement
(MVR), repeat balloon mitral valvuloplasty and the develop-
ment of NYHA class III or IV symptoms. Causes of death were
ascertained from patients’ medical records and their attending
physicians.
Statistical analysis. All continuous variables are presented
as mean 6 SD. Baseline and their corresponding postproce-
dural data were compared with use of the paired t test. For
comparisons of means of continuous data from two indepen-
dent groups, the two-sample t test for independent samples
with equal or unequal variances was used where appropriate.
To compare data from different institutions, one-way analysis
of variance (ANOVA) was employed. In addition, where
appropriate, continuous variables were categorized by use of
clinically reasonable cutoff points to define subgroups for the
purposes of analysis. Discrete data were compared by chi-
square analysis. To identify predictive factors for a technically
successful procedure as well as for the development of signif-
icant MR, multiple stepwise logistic regression analysis was
employed on significant explanatory variables from the univar-
iate analysis of demographic, hemodynamic, echocardio-
graphic and procedural variables. To identify independent
predictors of event-free survival, multiple stepwise Cox regres-
sion analysis was performed on significant explanatory vari-
ables from the univariate Cox proportional hazards regression
Figure 1. Ventriculographic frames of
a single valvuloplasty balloon dilated
across the stenotic mitral valve in the
right anterior oblique (A) and left an-
terior oblique (B) projections. (C):
schematic representation of the steer-
able left atrial guiding catheter (GC) in
the right anterior oblique (left) and left
lateral projection (right). By external
manipulations of the steering arm
(SA), the catheter’s distal tip is curved
so as to point directly at the mitral
orifice. The guidewire (GW) is stabi-
lized within the left atrium by the for-
mation of spirals.
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on demographic, hemodynamic, echocardiographic and proce-
dural variables. Analysis was performed in two steps, the first
including only baseline variables and the second including
procedural and postprocedural variables as well. All final
models were tested for two- and three-way interactions.
Kaplan-Meier estimates were used to determine event-free
survival rates for the entire FU population as well as for
patient subgroups defined on the basis of the independent
predictors of long-term event-free survival. Event-free survival
rates were expressed as estimated rate 6 SEM. All analyses
were performed by use of the SPSS version 7.5 statistical
package. A value of p , 0.05 was accepted as statistically
significant.
Results
Immediate results of RNBMV. Baseline hemodynamic
measurements and immediate results of RNBMV are shown in
Table 2. The procedure was completed in 438 cases. One case
of procedure abortion occurred early in the experience of the
center of origin in a patient with enlarged aorta and LV due to
aortic regurgitation in whom, although the guidewire was in
place, the length of the catheter proved insufficient for the
balloon to be positioned across the mitral valve. In the
remaining two cases of abortion, the procedure was completed
by the transseptal Inoue technique—with which operators
were more familiar at the time—in an effort to conserve time
as the patients developed pulmonary edema while LA entry
was being attempted.
Successful introduction of the guidewire into the LA was
achieved within 1–10 min in 440 procedures. The mean
duration of the procedure from the introduction of the LA
catheter into the LV until the removal of the balloon-
guidewire assembly was 24.6 6 8 min (12–60 min); mean
fluoroscopy time was 14.8 6 6 min (6–25 min).
A technically successful procedure, defined as an increase
in MVA $ 50% with postprocedural MVA $ 1.5 cm2 and final
MR # grade 21, was achieved in 388 cases (88%). Among the
53 technical failures, 15 (3.4%) developed significant (. grade
21) MR, 35 (7.9%) had a suboptimal result (increase in
MVA , 50% and/or final MVA , 1.5 cm2) while in three cases
retrograde balloon mitral dilatation was not attempted, as
mentioned above.
Stepwise multiple logistic regression analysis identified the
echocardiographic score, male gender, preprocedural MR and
previous commissuroromy as significant unfavorable predic-
tors of immediate outcome (Table 3). Compared with patients
with higher echocardiographic scores, those with scores # 8
had a greater postprocedural MVA (2.23 6 0.49 vs. 1.8 6 0.42
cm2, p , 0.001), a lower rate of significant postprocedural MR
(1.3% vs. 8.5%, p , 0.001) and a higher rate of procedure
success (97% vs. 66.4%, p , 0.001).
The use of the Inoue balloon catheter was associated with a
higher success rate than the use of the other balloon types;
conversely, use of the single-balloon was associated with the
lowest success rate.
Complications. Cardiac perforation, cardiac tamponade or
embolic events were not encountered. There was one
procedure-related death (0.2%) in a patient who developed
severe MR after valve dilatation and died after urgent MVR.
Mitral regurgitation. The degree of MR increased by one
grade in 78 patients (18%), by two grades in 15 patients
(3.4%), by three grades in 5 patients (1.1%) and by four grades
in 2 patients (0.5%). Overall, 15 patients (3.4%) had MR .
grade 21 at the end of the procedure. Emergency MVR was
necessitated in 2 of these patients (0.5%), 1 of whom died soon
after its completion, as mentioned above. Ten of the remaining
13 patients were eventually treated surgically within a period of
6.6 6 8 months (range, 1–27 months). Finally, 3 patients were
maintained stable under medical therapy for at least 6 months
after valvuloplasty, but data regarding their course thereafter
are not available.
Transesophageal echocardiography and examination of the
mitral valve after surgery revealed severe MR to be caused by
noncommissural anterior mitral leaflet tears in all cases. Pre-
procedural MR (p 5 0.003), the echocardiographic score (p 5
0.008) and NYHA functional class (p 5 0.038) were significant
independent predictors of the development of severe MR after
RNBMV.
Bleeding and vascular complications. Bleeding requiring
transfusion occurred in 4 (0.9%) patients (one of whom had
had sheathless RNBMV) while significant groin hematoma







Heart rate, bpm 82 6 12 81 6 12 NS
Mean left atrial pressure,
mm Hg
26 6 8 13 6 6 , 0.001
Mean transmitral gradient,
mm Hg
18 6 7 6 6 3 , 0.001
Mitral valve area, cm2 1.0 6 0.3 2.1 6 0.5* , 0.001
Cardiac output, liter/minute 4.0 6 0.8 4.5 6 0.8 , 0.001
Mean pulmonary artery pressure,
mm Hg
37 6 10 27 6 7 , 0.001
Pulmonary resistance,
dyneszszcm25
241 6 132 250 6 126 NS
*Estimated in 423 procedures without severe mitral regurgitation.
RNBMV 5 retrograde nontransseptal balloon mitral valvuloplasty; bpm 5 beats
per minute.
Table 3. Independent Predictors of Immediate Procedural Outcome
Variable b 6 SE Relative Risk p Value
Echocardiographic score 0.98 6 0.15 2.65 , 0.001
Male gender 1.42 6 0.50 4.13 0.005
Baseline mitral regurgitation 1.19 6 0.44 3.29 0.007
Previous commissurotomy 1.98 6 0.91 7.29 0.029
Balloon type 1.15 6 0.43 3.17 0.008
Constant 210.93 6 1.42 , 0.001
b 6 SE 5 regression coefficient 6 standard error.
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was noted in 5 patients (3 who had undergone sheathless
procedures and 2 Greek patients who were also part of the
group with severe bleeding).
Significant weakening of the femoral pulse was noted in 5
(1.1%) patients (2 of them after sheathless valvuloplasty). All
were treated effectively: one patient underwent femoral artery
(FA) balloon angioplasty, 3 were treated by thrombolysis and
one presented no functional problems and required no special
treatment.
Arrhythmias and intraventricular conduction disturbances.
Ventricular extrasystoles or salvos of nonsustained ventricular
tachycardia were recorded in most patients during the proce-
dure. Transient disturbances of atrioventricular conduction
were noted in 6 patients (1.4%), lasting 30 min in one case and
3 h in another, without need for special treatment. Distur-
bances of intraventricular conduction persisting for more than
24 h were observed in 10 patients (2.3%). Conduction was
restored on the second day in 7 patients and during the first
week in 2 patients while the defect persisted for 3 months in
one case.
Hospital stay. Mean hospital stay in the present series was
1.58 6 0.57 days (range, 1–4 days). Discharge was originally
permitted 48 h post-RNBMV, but in the last 100 Greek
patients and all Indian patients, hospital stay was reduced to 24
hs. Cases in which hospitalization was prolonged included all 5
patients with weakening of the femoral pulse, 4 patients with
severe postprocedural MR and 4 patients with bleeding com-
plications.
Follow-up. Of the 388 patients who had a successful
RNBMV, 3 patients did not return for reevaluation; the
remaining 385 patients were followed for 3.5 6 1.9 years
(range, 0.5–9.1 years). FU duration was 3.8 6 1.9 years and
2.6 6 1.2 years for Greek and Indian patients, respectively.
Seventeen patients were lost during FU and were censored at
the time of their last evaluation, while 1 patient died of
pancreatic cancer 34 months after the procedure and was
censored at the time of her death.
There was one cardiac death which occurred 26 months
after the procedure. Recurrence of NYHA class . II symp-
toms occurred in 35 patients, at a mean of 3.0 6 1.6 years after
RNBMV (range, 1.0–7.0 years); 19 patients were treated by
MVR, 2 patients underwent successful repeat RNBMV, while
14 patients were maintained under medical treatment.
The estimated event-free survival rates (freedom from
cardiac death, MVR, repeat valvuloplasty and NYHA class .
II) at 1, 2, 4 and 9 years were 100%, 96.9 6 0.9%, 89.8 6 1.9%
and 75.5 6 5.5%, respectively (Fig. 2). Rates during 4 years
post-RNBMV were similar for Greek and Indian patients (1
year: 100% vs. 100%; 2 year: 96.9 6 1.1% vs. 96.8 6 2.2%; 4
year: 89.4 6 2.1% vs. 91.9 6 3.9%, respectively, p 5 0.673).
Multiple stepwise Cox regression analysis on baseline variables
identified the echocardiographic score (p , 0.001), NYHA
functional class (p , 0.001), and preprocedural transmitral
pressure gradient (p 5 0.008) as significant independent
predictors of long-term event-free survival after RNBMV.
When procedural and postprocedural variables were included
in the analysis, postprocedural MVA emerged as a significant
predictor of long-term event-free survival (p 5 0.009), while
preprocedural pressure gradient was displaced from the model
(Table 4). Testing of the final Cox model for two- and
three-way interactions revealed postprocedural MVA (p 5
0.009) and the interaction between NYHA functional class and
echocardiographic score (p , 0.001) as the only independent
predictors of long-term event-free survival. Further analysis in
this respect was of limited value in our population because of
the small size of several resulting subpopulations, in which the
occurrence or absence of events had disproportionate effects
on survival rates.
The FU patient group was divided into subgroups on the
basis of the three independent significant predictors of long-
term outcome identified by the expanded model of Cox
analysis, and 9-year event-free survival rates for each subgroup
were estimated and compared. Rates were significantly higher
in patients with echocardiographic scores # 8 versus . 8
(88.1 6 4.8 vs 35.9 6 15.8%, p , 0.001, Fig. 3), in patients with
a postprocedural MVA $ 2 cm2 versus , 2 cm2 (88.1 6 3.6 vs.
57.5 6 10.7, p , 0.001, Fig. 4) and in patients in lower versus
higher NYHA functional class (NYHA class II: 97.8 6 2.2%,
NYHA class III: 76.1 6 5.7% and NYHA class IV: 31.9 6
23.1%, p , 0.001, Fig. 5).
Figure 2. Kaplan-Meier event-free survival curve for the entire
follow-up population. The number of patients available for observation
at the end of each year of follow-up is depicted under the horizontal
axis.
Table 4. Independent Predictors of Long-Term Event-Free Survival
Variable b 6 SE Relative Risk p Value
Echocardiographic score 0.43 6 0.08 1.54 , 0.001
NYHA functional class 0.92 6 0.34 2.49 0.008
Postprocedural mitral valve area 1.84 6 0.71 6.31 0.009
b 6 SE 5 regression coefficient 6 standard error.
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Effect of operator experience on immediate results, compli-
cations and intermediate long-term outcome. The mean post-
procedural MVA, rate of successful immediate result, rate of
suboptimal result, incidence of significant final MR, mean
procedure duration, mean fluoroscopy time and 4-year event-
free survival rates were compared between the cooperating
centers and (with the exception of the last variable) between
the first 100 and the subsequent 192 procedures performed at
the center of origin. Procedure duration and fluoroscopy time
were significantly shorter in high case-volume compared with
low case-volume centers, as well as in the last 192 compared
with the first 100 procedures performed at the center of origin
(p , 0.001 for all comparisons). No other significant differ-
ences were revealed.
Discussion
The present study demonstrated that RNBMV, performed
in centers with varying degrees of experience, produced a good
immediate outcome with an acceptable complication rate in
selected patients with symptomatic mitral stenosis. The benefit
from this procedure was maintained during intermediate long-
term FU in the majority of cases.
Retrograde LA catheterization. Multicenter application of
RNBMV confirmed previous experience regarding the feasi-
bility and safety of retrograde LA catheterization (8–13). LA
access by means of the special guiding catheter was achieved
invariably in this series, requiring a maximum of 10 min and
contributing to the favorable profile of RNBMV with regard to
total duration and duration of fluoroscopy. Steering of the LA
catheter within the LV was uneventful, even in patients with
marked mitral subvalvular deformity.
Avoidance of the technically demanding transseptal cathe-
terization probably also accounts for the steep learning curve
indicated by the comparison between early and late experience
at the center of origin and between results at the different
centers in the present study. A considerable impact of the
learning effect on the success and safety of balloon mitral
valvuloplasty has been demonstrated in reports with the trans-
septal technique (6,15–17).
Use of the route for LA access proposed by RNBMV may
prove particularly beneficial for patients in whom transseptal
catheterization is difficult to perform as are those with thick-
ened interatrial septum (usually resulting from previous car-
diac surgery), chest wall malformations or anomalies of the
inferior vena cava. Furthermore, it offers an alternative for
Figure 3. Kaplan-Meier event-free survival curves for patients with
echocardiographic score # 8 versus . 8. Format as in Figure 2.
Figure 4. Kaplan-Meier event-free survival curves for patients with
postprocedural mitral valve area (MVA) $ 2cm2 versus , 2cm2.
Format as in Figure 2.
Figure 5. Kaplan-Meier event-free survival curves according to base-
line symptom severity. Format as in Figure 2. NYHA 5 New York
Heart Association.
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“bailing-out” in case of a failed transseptal procedure. Con-
versely, it is not an option in patients with a prosthetic aortic
valve.
Immediate and intermediate long-term outcome of
RNBMV—comparison with transseptal mitral valvulo-
plasty. Conclusions regarding comparison of RNBMV with
transseptal balloon mitral valvuloplasty based on the present
report should be drawn with caution, taking into account
potential differences between our patient population and those
of reports employing the transseptal approach, particularly in
North American centers, which have often included large
numbers of nonideal candidates for balloon mitral valvulo-
plasty.
Keeping these considerations in mind, it could be stated
that multicenter application of RNBMV produced comparable
results to those yielded by the transseptal approach in single
large-volume center and multicenter studies, with respect both
to procedure success rates and magnitude of immediate hemo-
dynamic alterations (6,15,17–23), as well as to the clinical
course of patients during long-term FU (24–26).
The inverse relation between the extent of mitral valve
deformity and the benefit derived by transseptal balloon mitral
valvuloplasty has been well-established (14,18,23,27–29). Our
data indicate that this is equally true in the case of RNBMV.
The echocardiographic score was the most important indepen-
dent predictor of immediate results in the present study, and
patients with a score # 8 had significantly higher rates of
procedure success, greater final MVA and a lower incidence of
significant postprocedural MR, compared with patients with
higher echocardiographic scores.
The intermediate long-term event-free survival after
RNBMV was also predicted independently by mitral anatomy,
with estimated 9-year rates being 88% for patients with
echocardiographic scores # 8 versus 36% for those with
scores . 8. Additional significant predictors of event-free
survival included the NYHA functional class and postproce-
dural MVA, revealing intermediate long-term prognosis after
RNBMV as a function of disease severity at the time of the
intervention and immediate procedural results; such a concept
has also been outlined by the results of operators performing
the transseptal approach (24,26).
Complications of RNBMV. The safety profile of RNBMV
was favorable in the present series. Cardiac perforation and
cardiac tamponade were not encountered in any case, in
contrast to rates ranging between 0.2% and 6.7% with the
transseptal technique (6–7,15,17,19–21). While nontransseptal
LA entry diminishes the risk of LA wall injury, the possibility
of LV perforation might be expected to persist with RNBMV;
we attribute the lack of its occurrence to two procedural
elements: 1) the stabilization of the guidewire within the LA
throughout the procedure, which decreases significantly the
likelihood of displacement of the balloon from the mitral
orifice during inflation, and 2) the position of the guidewire
within the LV, which constrains the balloon catheter’s tip
during its insertion into this chamber and prevents it from
approaching closely the LV apex.
Development of severe MR was the most significant com-
plication in the present series, occurring in 3.4% of cases
compared with rates between 1% and 17% reported during
transseptal valvuloplasty (6,7,19–22,30–32). The etiologic di-
versity of severe MR development following the latter tech-
nique (30–32) was not encountered with RNBMV; absence of
its induction by papillary muscle or chordal rupture attests to
the safety of retrograde LA catheterization.
Concerns regarding retrograde mitral valvuloplasty have
focused predominantly on the possibility of FA injury as a
result of its cannulation by large introductory sheaths. The rate
of this complication in our study (1.1%) was not insignificant,
although it was lower than that previously encountered with
balloon aortic valvuloplasty (27,33), probably as a result of the
young age of our patients. FA damage occurred exclusively in
either sheathless procedures or during the early experience in
Greece, when comparably more traumatic sheaths were em-
ployed. In contrast, use of 12 F sheaths in the last 250 Greek
patients did not lead to FA damage. Further reduction of the
incidence of this complication may be anticipated by future use
of sheaths of smaller caliber in appropriate cases (e.g., use of
10 F sheaths when use of a single 25-mm balloon is planned for
mitral valve dilatation).
Conclusions. The first multicenter application of RNBMV
yielded immediate and intermediate long-term results similar
to those achieved with the transseptal technique. Transarterial
LA access avoided serious complications associated with trans-
septal catheterization, whereas it occasionally led to FA injury.
Overall consideration of RNBMV suggests that it represents a
reliable alternative to the transseptal approach, and may thus
help broaden the application of percutaneous balloon mitral
valvuloplasty.
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